Endometriosis is a chronic, inflammatory disease with considerable symptom load in affected female patients. Cyclic pain (associated with menstruation) dominates in most patients, but few patients suffer from persistent non-cyclic …
Objectives: To evaluate the impact of hormonal therapy on the evolution of painful symptoms in premenopausal women with adenomyosis, with or without concomitant endometriosis, over an 18-month follow-up period. This …
Background: Desmoid tumors (DTs) are rare, locally aggressive soft-tissue neoplasms that often affect women of reproductive age. Pregnancy and prior abdominal surgery or trauma have been associated with tumor development …
Gonadotropin-releasing hormone pulsatility is under the influence of hypothalamic neuropeptides, especially neurons expressing kisspeptin, neurokinin B, and dynorphin. These hypothalamic cells are called KNDy neurons. By integrating hormonal and environmental …
Dyspareunia is a common symptom in women with endometriosis, yet its positional dependency is not routinely assessed in clinical practice.
Endometriosis in adolescents presents unique diagnostic and management challenges compared to its manifestation in adult women. The symptoms can vary significantly among individuals, often resulting in a substantial delay in …
Endometriosis (ENDO) is a painful, chronic gynecological disease widely affecting women globally. While traditionally classified as a hormonal disorder, ENDO is now increasingly recognized as a multifaceted immune-mediated syndrome driven …
Endometriosis is an inflammatory disorder characterized by ectopic endometrial-like tissue, affecting approximately 10% of women. It significantly impairs quality of life through symptoms such as dysmenorrhea, pelvic pain, and infertility. …
Endometriosis is a chronic inflammatory disease characterized by pelvic pain and infertility, with oxidative stress playing a key role in its pathogenesis. Although antioxidant supplementation has been proposed as a …
To demonstrate, using actual insurance data, that benign pelvic conditions are associated with increased healthcare costs and that these costs increase further with each additional coexisting benign pelvic diagnoses.